Pharmacogenomics research and its clinical implementation in Thailand: Lessons learned from the resource-limited settings

Several barriers present challenges to implementing pharmacogenomics into practice. This review will provide an overview of the current pharmacogenomics practices and research in Thailand, address the challenges and lessons learned from delivering clinical pharmacogenomic services in Thailand, emphasize the pharmacogenomics implementation issues that must be overcome, and identify current pharmacogenomic initiatives and plans to facilitate clinical implementation of pharmacogenomics in Thailand. Ever since the pharmacogenomics research began in 2004 in Thailand, a multitude of pharmacogenomics variants associated with drug responses have been identified in the Thai population, such as HLA-B*15:02 for carbamazepine and oxcarbazepine, HLA-B*58:01 for allopurinol, HLA-B*13:01 for dapsone and cotrimoxazole, CYP2B6 variants for efavirenz, CYP2C9*3 for phenytoin and warfarin, CYP3A5*3 for tacrolimus, and UGT1A1*6 and UGT1A1*28 for irinotecan, etc. The future of pharmacogenomics guided therapy in clinical settings across Thailand appears promising because of the availability of evidence of clinical validity of the pharmacogenomics testing and support for reimbursement of pharmacogenomics testing. (C) 2021 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.